uploads/2017/07/Rare-disease-revenues-1.png

What to Expect from Pfizer’s Rare Disease Franchise in 2017

By

Updated

BeneFix revenue trends

In 2016, Pfizer’s (PFE) BeneFix reported revenues of ~$712 million, which reflected a ~5% YoY (year-over-year) fall. In 1Q17, BeneFix generated revenues of ~$149 million, which represented a ~19% YoY fall and a 12% QoQ (quarter-over-quarter) fall.

BeneFix is a recombinant coagulation factor IX used for the management of bleeding in individuals with hemophilia B. The increasing competition in the US market and the increased adoption of extended half-life treatment options led to the decline in BeneFix revenues in 1Q17. The drug faces stiff competition from Biogen’s (BIIB) Alprolix.

Article continues below advertisement

Genotropin (somatropin) revenue trends

In 2016, Genotropin reported revenues of ~$579 million, or ~6% lower YoY. In 1Q17, Genotropin generated revenues of ~$104 million, or ~17% lower YoY and ~32% lower QoQ.

Genotropin is a recombinant HGH (human growth hormone) indicated for the treatment of growth hormone deficiency. In children, the drug is also used for the treatment of Turner syndrome, Prader-Willi syndrome, and idiopathic short stature. The drug faces stiff competition from Novartis’s (NVS) Omnitrope.

Refracto AF-Xyntha revenue trends

In 2016, Refracto AF-Xyntha reported revenues of ~$140 million, representing a ~4% YoY rise. In 1Q17, Refracto AF-Xyntha generated revenues of ~$140 million, or ~9% higher YoY and 4% lower QoQ.

Xyntha is a recombinant antihemophilic factor indicated in individuals with hemophilia A for the prevention of bleeding episodes.

Somavert revenue trends

In 2016, Pfizer’s Somavert reported revenues of ~$232 million, or ~6% higher YoY. In 1Q17, Somavert generated revenues of ~$56 million, or ~2% higher YoY and 5% lower QoQ.

Somavert (pegvisomant) is a growth hormone receptor (or GHR) antagonist used for the treatment of individuals with acromegaly, who have not responded adequately to surgery or radiation therapy.

The drug faces stiff competition from Novartis’s Sandostatin LAR Depot, and Ipsen Biopharmaceuticals’ (IPSEY) Somatuline Depot. Notably, the iShares US Healthcare ETF (IYH) has ~6.3% of its total portfolio holdings in Pfizer.

Advertisement

More From Market Realist